Oragenics, Inc. (NYSEAMERICAN:OGEN) Short Interest Up 24.3% in February

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the target of a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 570,220 shares, an increase of 24.3% from the February 12th total of 458,764 shares. Based on an average daily volume of 844,062 shares, the short-interest ratio is presently 0.7 days. Currently, 14.9% of the shares of the company are sold short. Currently, 14.9% of the shares of the company are sold short. Based on an average daily volume of 844,062 shares, the short-interest ratio is presently 0.7 days.

Institutional Investors Weigh In On Oragenics

Several institutional investors have recently added to or reduced their stakes in OGEN. Clear Street LLC bought a new position in Oragenics during the second quarter worth about $270,000. Bank of America Corp DE raised its position in shares of Oragenics by 7,374.0% in the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after purchasing an additional 15,338 shares during the period. Sabby Management LLC purchased a new stake in shares of Oragenics during the 3rd quarter valued at approximately $77,000. DRW Securities LLC lifted its stake in shares of Oragenics by 82.4% during the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after buying an additional 50,900 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Oragenics in the 4th quarter worth approximately $26,000. 18.71% of the stock is owned by hedge funds and other institutional investors.

Oragenics Stock Performance

NYSEAMERICAN:OGEN traded down $0.09 during trading hours on Monday, reaching $0.80. The stock had a trading volume of 232,617 shares, compared to its average volume of 601,114. The stock has a market cap of $3.42 million, a P/E ratio of -0.07 and a beta of 1.09. The stock has a 50 day simple moving average of $0.82 and a 200 day simple moving average of $1.00. Oragenics has a 12-month low of $0.61 and a 12-month high of $9.60.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.